InvestorsHub Logo
Followers 67
Posts 1293
Boards Moderated 0
Alias Born 08/12/2014

Re: None

Monday, 06/05/2023 2:52:53 PM

Monday, June 05, 2023 2:52:53 PM

Post# of 700017
Anything has reason. The strange/abnormal way of nwbo communication, for example today instead of pr-ing Dr. Bosch's gorgeous presentation at ASCO, nwbo sends email to al investors who have mostly already loaded up -- obviously nwbo doesn't want to ruffle feathers of those concerned, including FDA, and those warped who would take any chance to bash and accuse the company of illegal marketing.

The very detailed, data rich presentation, for instance, full antigens uptake by DCVax vaccine from the tumors, and stimulated, multiplied and generation T-cells, B-cells seems to suggest the company may go on the route of approvals bigger and grenadier than what we have expected -- tissue/tumor agnostic -- at least exploratory for approvals for many other solid tumors.

Whatever is going on behind the scene, DCVax-L will be approved for nGBM and rGBM. We can wait for approvals for other indications later when the company has more concrete evidence to support the nature of DCVax-L as tumor agnostic.

Without the notice and interest of the general public, it may be easy for the accused MMs to contain the price, but those who know what we have, it's yet an opportunity to buy at such unbelievably low price.
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News